Spondyloarthritis & psoriatic arthritis
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations
Authors' conclusion
The emergence of agents with novel mechanisms of action in recent years, such as interleukin 17 (IL-17), IL-12/23, IL-23, and Janus kinase inhibitors, has significantly expanded the available treatment options for dactylitis.
Study context
- Population
- Interventional trials in PsA reporting dactylitis-related outcomes, published 2013–2020 (MEDLINE, Embase, Cochrane Library)
- Participants
- 16,752 participants40 randomized clinical trials (RCTs)
- Outcome
- Dactylitis assessment in RCTs reporting dactylitis-related outcomes
Methodological detailsinforming the 2021 GRAPPA treatment recommendations
- Informing the 2021 GRAPPA treatment recommendations
Main finding
As reported in the abstract
Dactylitis assessed as a secondary outcome
97.5%
RCTs not employing a specific dactylitis measure or instrument
more than 40%
Original publication
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. Published 1 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →